MedTrace Logo

Donepezil and Brain Activity Patterns in Those at Risk For Alzheimer's Disease

NCT00408525 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2018-02-05

No results posted yet for this study

Summary

The purpose of the study is to examine patterns of brain activity in people who are at risk for memory problems (e.g., Alzheimer's disease or dementia)before and after the medication donepezil. Although genetic testing will be done, the results will not be shared with study participants.

Once the genetic testing is completed subjects may continue to the second phase of the study. During this time they will be asked to take the medication donepezil (which is approved by the FDA for the treatment of Alzheimer's disease).

Donepezil is not FDA approved for healthy volunteers and is therefore considered investigational in this study.

Conditions

Interventions

DRUG

donepezil

donepezil 5 mg tablets, total dose per day 10 mg for 6 week duration of study. Taken once per day.

Sponsors & Collaborators

  • Vanderbilt University

    lead OTHER

Principal Investigators

  • Harry E Gwirtsman, M.D. · Vanderbilt University Medical Center

Study Design

Allocation
NA
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-12-31
Primary Completion
2012-08-24
Completion
2012-08-24

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00408525 on ClinicalTrials.gov